Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Mar 1;30(8):1066–1071. doi: 10.1177/13524585241233177

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2024

This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 1. — The change in full-field P100 latency over time. (a) Representative averaged VEP signals from the left eye of a participant across the three assessments: baseline and month 6 of the CCMR One trial, and the follow-up visit 2 years later. This participant had no history of clinical optic neuritis and had been randomised to bexarotene in the original trial. (b) and (c) The change in P100 latency for all eyes (b) and for just those eyes with a baseline P100 latency >118 ms (c) over course of the baseline and 6-month visits of CCMR One, and the follow-up assessment, divided by treatment group. (d) The percentage of eyes with more than 6 ms improvement in latency delay.